Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment.
Pyoderma gangrenosum (PG) is a rare inflammatory neutrophilic disorder with prototypical clinical presentations. Its pathophysiology is complex and not fully explained. Recent information regarding the genetic basis of PG and the role of auto-inflammation provides a better understanding of the disea...
| Publicado en: | American Journal of Clinical Dermatology Vol. 18; no. 3; pp. 355 - 373 |
|---|---|
| Autores principales: | , , , , |
| Formato: | pictorial review tables/charts Journal Article |
| Publicado: |
Springer Nature
Jun2017
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=122919400&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 122919400 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11750561 C4Q jtl: American Journal of Clinical Dermatology issn: 11750561 maglogo: N pubinfo: dt: Jun2017 vid: 18 iid: 3 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 122919400 122919400 144029893 122919400 10.1007/s40257-017-0251-7 122919400 ppf: 355 ppct: 18 formats: tig: atl: Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment. aug: au: Alavi, Afsaneh French, Lars Davis, Mark Brassard, Alain Kirsner, Robert affil: Division of Dermatology, Department of Medicine , Women's College Hospital, University of Toronto , 76 Grenville St, 5th Floor Toronto M5S 1B2 Canada sug: subj: Pyoderma Gangrenosum Pyoderma Gangrenosum Diagnosis Pyoderma Gangrenosum Therapy Pyoderma Gangrenosum Physiopathology Inflammation Comorbidity Disease Management ab: Pyoderma gangrenosum (PG) is a rare inflammatory neutrophilic disorder with prototypical clinical presentations. Its pathophysiology is complex and not fully explained. Recent information regarding the genetic basis of PG and the role of auto-inflammation provides a better understanding of the disease and new therapeutic targets. PG equally affects patients of both sexes and of any age. Uncontrolled cutaneous neutrophilic inflammation is the cornerstone in a genetically predisposed individual. Multimodality management is often required to reduce inflammation, optimize wound healing, and treat underlying disease. A gold standard for the management of PG does not exist and high-level evidence is limited. Multiple factors must be taken into account when deciding on the optimum treatment for individual patients: location, number and size of lesion/ulceration(s), extracutaneous involvement, presence of associated disease, cost, and side effects of treatment, as well as patient comorbidities and preferences. Refractory and rapidly progressive cases require early initiation of systemic therapy. Newer targeted therapies represent a promising pathway for the management of PG, and the main focus of this review is the management and evidence supporting the role of new targeted therapies in PG. pubtype: Academic Journal doctype: pictorial review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|